 MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC ACCESSWIRE April 29, 2021 RepliCel Life Sciences Inc. OTC PINK:REPCF TSXV:RP FRA:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, announced today it has closed the second tranche of the investment by MainPointe Pharmaceuticals MainPointe as outlined in the share purchase agreement signed earlier this year by the parties. This second tranche involved MainPointes purchase of 1,777,778 common shares issued by RepliCel in exchange for CAD 1,200,000 which has now been received by the Company. 